Dual Synergistic Tumor‐Specific Polymeric Nanoparticles for Efficient Chemo‐Immunotherapy
Advanced Science · 2023-10 · 10 (29)
DOI: 10.1002/advs.202301216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 07.08.2023. Verfasst von Jiajia Xiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Smart Biomaterials and Key Laboratory of Biomass Chemical Engineering of Ministry of Education, College of Chemical and Bi…. Hauptthemen laut MEDLINE: Immunotherapy, Nanoparticles, Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program, National Natural Science Fund of China, Zhejiang Provincial Key Research and Development Program.
Abstract (Originalsprache)
Chemo‐immunotherapy has made significant progress in cancer treatment. However, the cancer cell self‐defense mechanisms, including cell cycle checkpoint and programmed cell death‐ligand 1 (PD‐L1) upregulation, have greatly hindered the therapeutic efficacy. Herein, norcantharidin (NCTD)‐platinum (Pt) codelivery nanoparticles (NC‐NP) with tumor‐sensitive release profiles are designed to overcome the self‐defense mechanisms via synergistic chemo‐immunotherapy. NC‐NP remains stable under normal physiological conditions but quickly releases 1,2‐diaminocyclohexane‐platinum(II) (DACHPt, a parent drug of oxaliplatin) and NCTD in response to the tumor acidity. NCTD inhibits protein phosphatase 2A (PP2A) activity to relieve cell cycle arrest and downregulates the tumor PD‐L1 expression to disrupt the programmed cell death‐1 (PD‐1)/PD‐L1 interaction, synergistically enhancing Pt‐based chemotherapy and immunogenic cell death‐induced immunotherapy. As a result, NC‐NP exhibits potent synergistic cytotoxicity and promotes T cell recruitment to generate robust antitumor immune responses. The dual synergism exhibits potent antitumor activity against orthotopic 4T1 tumors, providing a promising chemo‐immunotherapy paradigm for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Key Laboratory of Smart Biomaterials and Key Laboratory of Biomass Chemical Engineering of Ministry of Education, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, 310027, China.
- ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou, 311215, China.
ORCID-Profile: Zhuxian Zhou
Förderung
- National Key Research and Development Program
- National Natural Science Fund of China
- Zhejiang Provincial Key Research and Development Program
- ZJU-Hangzhou Global Scientific and Technological Innovation Center
- National Key Research and Development Program of China
Zitieren
APA
Xiang, J., Liu, K., Xu, H., Zhao, Z., Piao, Y., Shao, S., Tang, J., Shen, Y., & Zhou, Z. (2023). Dual Synergistic Tumor‐Specific Polymeric Nanoparticles for Efficient Chemo‐Immunotherapy. Advanced Science, 10(29). https://doi.org/10.1002/advs.202301216
Vancouver
Xiang J, Liu K, Xu H, Zhao Z, Piao Y, Shao S, et al. Dual Synergistic Tumor‐Specific Polymeric Nanoparticles for Efficient Chemo‐Immunotherapy. Advanced Science. 2023;10(29). doi:10.1002/advs.202301216
BibTeX
@article{Xiang2023,
author = {Xiang, Jiajia and Liu, Kexin and Xu, Hongxia and Zhao, Zhihao and Piao, Ying and Shao, Shiqun and Tang, Jianbin and Shen, Youqing and Zhou, Zhuxian},
title = {Dual Synergistic Tumor‐Specific Polymeric Nanoparticles for Efficient Chemo‐Immunotherapy},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {29},
doi = {10.1002/advs.202301216}
}
EUVIMED